Today, Huikang (300451) rose 8.72% to close at 10.85 yuan.
On October 27, 2021, Wen Xuechen, a researcher at Sino-Thai Securities, issued a research report on start-up Huikang, "the income of the medical industry maintained high growth, and the gross net profit margin increased." the research newspaper gave Huikang a "buy" rating. The Securities Star data Center calculates that the accuracy of the author's profit forecast for this stock is 91.0% based on the research data released in the past three years.
Securities Star data center calculations show that the more accurate forecast of the stock's earnings of the analyst team is GF Securities Co., LTD. 's Liu Xuefeng.
Overview of Venture Huikang (300451) stocks:
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.